INTRODUCTION
The family of IL (interleukin)-6-type cytokines comprises IL-6, IL-11, LIF (leukaemia inhibitory factor), OSM (oncostatin M), CNTF (ciliary neurotrophic factor), CT-1 (cardiotrophin-1) and CLC (cardiotrophin-like cytokine). They activate target genes involved in differentiation, survival, apoptosis and proliferation. The members of this cytokine family have pro-as well as antiinflammatory properties and are major players in haematopoiesis, as well as in acute-phase and immune responses of the organism. IL-6-type cytokines bind to plasma membrane receptor complexes containing the common signal transducing receptor chain gp 130 (glycoprotein 130). Signal transduction involves the activation of JAK (Janus kinase) tyrosine kinase family members, leading to the activation of transcription factors of the STAT (signal transducers and activators of transcription) family. Another major signalling pathway for IL-6-type cytokines is the MAPK (mitogen-activated protein kinase) cascade ( Figure 1 ). Recent reviews on the subject of signal transduction via the JAK/STAT pathway have been published [1] [2] [3] . The present review focuses on advances made during the last 5 years in structural/functional aspects of IL-6-type cytokine receptor activation, JAK-receptor interactions, STAT activation, signal modul- an α-receptor subunit has been postulated for CT-1 [5] , but since this putative receptor protein has not been cloned yet its existence is questionable. IL-6 and IL-11 are the only IL-6-type cytokines that signal via gp130 homodimers. The remaining IL-6 type cytokines signal via heterodimers of either gp130 and the LIFR (LIF, CNTF, CT-1 and CLC) or gp130 and the OSMR (OSM). Human OSM has the exceptional capability to recruit two different receptor complexes. It forms both LIFR-gp130 and OSMR-gp130 heterodimers. LIF and OSM directly engage their signalling receptor subunits without requirement for additional α-receptor subunits ( Figure 2 ) [4, 6] .
Although gp130 is ubiquitously expressed, the number of cells that respond to a certain IL-6-type cytokine is limited, since the expression of the other receptor subunits, especially of the α-receptors, is more restricted and tightly regulated. The function of the α-receptors to render cells sensitive to the respective cytokine, however, can also be taken over by the soluble form of the α-receptors lacking the transmembrane and cytoplasmic parts. This is one of the rare situations in which a complex of cytokine and soluble receptor can act agonistically instead of antagonistically. Soluble forms of cytokine receptors in vivo are formed either by limited proteolysis (shedding) of membrane-bound receptors or by translation from an alternatively spliced mRNA [4] . In the case of IL-6, the scenario is more complex, since soluble forms for IL-6Rα (sIL-6Rα) and gp130 (sgp130) are both present in human serum. It has been demonstrated that sIL-6Rα potentiates the antagonistic activity of sgp130. Thus the naturally occuring combination of sIL-6Rα and sgp130 might act as a kind of buffer to modulate systemic responses to circulating IL-6 [7] .
Although the cytoplasmic part of the IL-6Rα is dispensable for receptor complex formation and signal transduction, a function has recently been assigned to this part of the protein [8] : it contains a tyrosine-based and a dileucine-type motif which direct sorting of IL-6Rα to the basolateral membrane of polarized cells. Similarly, also targeting of gp130 to the basolateral membrane is dependent on a sorting motif within its cytoplasmic part. In certain cell types, a localization of gp130 in plasma membrane microdomains, such as lipid rafts and caveolae, has been observed [9] [10] [11] . This might be a prerequisite for special signalling functions of the receptor.
For CLC, the most recently discovered IL-6-type cytokine [6] , a very special mechanism of secretion and receptor recruitment has been described [12, 13] . To become secreted, CLC must be coexpressed with either CLF-1 (cytokine-like factor-1) or CNTFRα. CLF-1 resembles a soluble cytokine receptor and specifically binds CLC. After secretion of the CLC-CLF-1 or CLC-CNTFRα complexes, signalling is dependent on CNTFRα and occurs via gp130-LIFR heterodimers.
KSHV-IL-6 (Kaposi's sarcoma-associated herpes virus IL-6) [14] and Rhesus macaque rhadinovirus IL-6 [15] are viral variants of the IL-6-type cytokines that exhibit low similarity to IL-6 and signal by recruitment of gp130. Interestingly, KSHV-IL-6 binds the gp130 homodimer in the absence of any α-receptor [16] , but with lower affinity as compared with IL-6-IL-6Rα-gp130 ternary complexes.
Structure and function of IL-6-type cytokines and their receptors:
α-helices meet β-sheets IL-6-type cytokines form a subfamily of the helix bundle cytokines. All IL-6-type cytokines comprise four long α-helices termed A, B, C and D, which are arranged in a way that leads to an up-up-down-down topology ( Figure 3 ). In contrast with IL-6, and presumably also IL-11, where all the helices are straight, the A helix of LIF, OSM and CNTF is kinked [17, 18] . This structural divergence might reflect differences in the mechanisms of receptor recruitment, since the straight cytokines signal via gp130 homodimers, whereas the kinked cytokines signal via LIFRgp130 or OSMR-gp130 heterodimers.
The ectodomains of the receptors involved in IL-6-type cytokine signalling comprise an array of FNIII (fibronectin type III)-like and Ig-like domains (Figure 4 ). Each receptor contains at least one cytokine-binding module (CBM) that comprises two FNIII-domains. A CBM is characterized by conserved structural features, such as a distinct pattern of cysteine residues in the Nterminal domain and a WSXWS motif in the C-terminal domain.
In each receptor an Ig-like domain is located N-terminally to the membrane-proximal CBM. In contrast with the α-receptors, the receptors that initiate signal transduction have three additional membrane-proximal FNIII domains [4] . How the different IL-6-type cytokines bind specifically to their receptors has been intensely investigated during recent years. Mutagenesis studies have identified distinct areas on the surface of the cytokines (termed 'sites') which specifically interact with the respective receptors. Common to all IL-6-type cytokines is site II that interacts with the CBM of gp130. The second signalling receptor, either a second gp130 or LIFR or OSMR, is recruited to site III [4] . A surprise was the discovery that site III is recognized by the Ig-like domain of gp130, LIFR or OSMR [19] [20] [21] [22] . Thus in the homodimer two different binding epitopes of gp130 are involved in ligand recognition [23] . When a non-signalling α-receptor is involved in the receptor complex, it binds with its CBM to site I [4] . The interaction sites predicted by mutagenesis studies have recently been confirmed by the X-ray structure of KSHV-IL-6 bound to a soluble gp130 fragment comprising the CBM and the Ig-like domain [24] . When the recently solved structure of the IL-6Rα ectodomain [25] is accommodated into this structure, a reliable model of the membrane-distal part of Solved structures for vIL-6/gp130, gp80, STAT3 and SHP2 (Brookhaven Databank accession numbers 1I1R, 1N26, 1BG1 and 2SHP respectively), as well as molecular models of a JAK2 kinase domain and SOCS1 (amino acids , are represented. In the extracellular part, IL-6 is shown in red, IL-6Rα in green and the two gp130 molecules of the homodimer in cyan and blue. The domains D4-D6 of gp130, as well as the FERM, SH2 and kinase-like domains of the JAKs, are depicted as coloured ovals with the sizes corresponding to the tenascin FNIII, moesin FERM, SH2 and insulin receptor kinase domains. Arrangement of D4-D6 of gp130 was proposed by Kurth et al. [36] . The cytoplasmic parts of gp130 and gp80, as well as the non-structured extracellular 'stalk' region of gp80 [25] , are represented as blue and green lines with lengths corresponding to non-structured polypeptides. The positions of the six tyrosine residues of gp130 are indicated and the box1 and box2 regions are drawn as black lines. The cytoplasmatically associated proteins are depicted in the colour code corresponding to Figure 3 . Note that in the case of STATs, the N-terminal domain, as well as the C-terminal transactivation domain, are not represented. Re-orientation of the transmembrane region in response to ligand binding is indicated by circular arrows.
the hexameric IL-6-sIL-6Rα-sgp130(D1-D3) complex can be constructed ( Figure 5 ).
The binding of IL-6-type cytokines to their receptors leads to a rapid internalization of the ligand. So far, no internalization signals have been identified in the α-receptors. Thus internalization is mediated by the signal transducing receptor subunits [4] . Indeed, in gp130 [26] and the LIFR [27] dileucine-like motifs have been identified that are required for receptor-mediated ligand internalization. Internalization of gp130 seems to be independent from ligand binding [28] , and is modulated by phosphorylation at Ser 782 [29] which is located adjacent to the dileucine motif. Some evidence has been provided that under certain circumstances gp130 and LIFR are degraded after internalization [30] [31] [32] .
There are several reports showing that unrelated receptors are involved in signal transduction of IL-6-type cytokines: stimulation of fibrosarcoma cells with OSM leads to a pronounced phosphorylation of the IFN (interferon) receptor chain 1 [33] , and in murine embryonic fibroblasts lacking the IFNα-IFNβ signalling complex IL-6 signals are significantly reduced [34] . Moreover, it was reported that ErbB2 forms a complex with gp130 in an IL-6-dependent manner in prostate carcinoma cells [35] .
Receptors at work: let's do the twist
Why do the signalling receptors of the IL-6-type cytokines contain additional membrane-proximal FNIII domains that are not involved in ligand binding? It has been shown that these domains are necessary for coupling ligand binding and signal transduction, since deletion of these domains leads to signalling incompetent receptors [36, 37] . A domain model of the IL-6 receptor complex [36] , as well as the recent X-ray data [24] , show that the C-termini of the two CBMs in the gp130 homodimer are separated by a distance of about 9 nm. The membrane-proximal FNIII domains might bridge this distance so that the cytoplasmic parts are in close enough proximity to become activated by the associated JAKs ( Figure 5 ). This assumption is supported by a recent study on the role of the gp130 FNIII domains for heterodimerization with the LIFR [38] .
What are the prerequisites for cytokine receptor activation? Is it sufficient to bring two receptors into close proximity or has a well defined conformation to be adjusted for signalling to occur? For the gp130 homodimer, studies using agonistic monoclonal antibodies have contributed to clarify this issue. Unlike many other receptors, efficient gp130 activation could not be achieved by a single antibody, but requires the action of two distinct monoclonal antibodies [39, 40] . The minimal requirement for receptor activation is one intact antibody and the Fab (fragment antigen binding) of the second antibody. This finding has been interpreted in a way that the bivalent intact antibody enforces receptor dimerization and the monovalent Fab adjusts the conformation required for JAK activation and downstream signalling [40] .
For some receptors, including cytokine receptors, pre-dimerization or pre-oligomerization is discussed [41] [42] [43] [44] . In these cases, the ligand does not actively induce receptor dimerization, but stabilizes a preformed receptor complex and initiates receptor activation by additionally inducing a conformational change. In the case of gp130, this concept bears some intrinsic problems since gp130 interacts with several different receptors. Therefore, the requirement for pre-dimerization with another signal transducing receptor or an α-receptor would predetermine gp130 to interact with certain, but not all, IL-6-type cytokines.
In order to transfer the information of a ligand-adjusted conformation from the outside to the inside of the cell, it seems conceivable that the transmembrane domain of cytokine receptors adopts a rigid structure. Indeed, recent studies have suggested that the transmembrane and membrane-proximal intracellular regions of cytokine receptors adopt an α-helical conformation. Interestingly, insertion of one to four alanine residues into the membrane-proximal intracellular region of gp130 demonstrated that full activation of the receptor (i.e. induction of target genes) was only obtained with the wild-type and the + 3A-mutant [45] . An independent study on the EpoR (erythropoietin receptor) juxtamembrane intracellular region also described an α-helical dependency of Epo-induced signal transduction [46] . These results were explained by the hypothesis that insertion of one alanine residue twists the receptor by approx. 110
• , resulting in a position very different from the wild-type receptor state which might prevent efficient signal transduction. In contrast, insertion of three extra alanine residues into an α-helix should lead to a rotation of approx. 330
• , twisting the receptor back, close to its native position. Interestingly, within the cascade of signalling events cytokine receptors seem to differ in the step that is sensitive towards orientation. While for gp130, the STATs were found to depend on a specific conformation in order to become phosphorylated, for the EpoR the receptor phosphorylation seems to be sensitive to changes in orientation. Constantinescu et al. [46] identified a hydrophobic motif in the EpoR membrane-proximal domain (Leu 253 , Ile 257 and Trp 258 ) which is conserved in many cytokine receptors and needs to be precisely orientated in order to promote signalling.
Receptor-JAK interaction: more than just a rendez-vous
As found for many other cytokines, IL-6-type cytokines also rapidly induce the activation of tyrosine kinases of the JAK family. The signal transducing chains gp130, LIFR and OSMR bind to JAK1, JAK2 and TYK2 [47] [48] [49] [50] . Of these, JAK1 plays an essential role, because in cells lacking JAK1 IL-6 signal transduction is greatly impaired [51, 52, 134] .
The interaction between gp130 and JAK1 is very tight and long-lasting: a recent FRAP (fluorescence recovery after photobleaching) analysis with fluorescent fusion proteins revealed that JAK1 does not diffuse like a typical cytoplasmic protein.
Instead, its mobility is approx. 100-fold lower and similar to the one of the transmembrane protein gp130. Interestingly, immobilization of gp130 by antibodies leads to a concomitant immobilization of JAK1, indicating that there is no rapid exchange of JAK1 between different receptors (B. Giese and G. Müller-Newen, unpublished work).
JAKs bind to the membrane-proximal region of cytokine receptors, which contains conserved so-called box1 and box2 motifs. Deletion of the proline-rich box1 or mutation of two critical proline residues within box1 abrogates receptor binding of JAKs to gp130, OSMR or LIFR [49, 53, 54] . Box2 of gp130, a sequence dominated by hydrophobic amino acids followed by charged ones, contributes to JAK binding, presumably by increasing the affinity; a gp130 construct lacking box2 coprecipitates with JAK1 only when the kinase is over-expressed [55] . This demonstrates the sensitivity of the experimental readout to variations in expression levels of the interaction partners and helps to explain previous somewhat conflicting results on the importance of the gp130 box2 region [56] [57] [58] . Finally, also the interbox1-2 region of gp130 is critical, e.g. mutation of a single amino acid (Trp 666 ) abrogates JAK binding and thereby leads to inactivation of the receptor complex [54] . Thus the interaction surface with JAKs may involve multiple contact sites within the receptor.
In contrast with the modular character of STAT recruitment motifs, the JAK-recruiting region loses its functionality upon transfer within the cytokine receptor chain; addition of the box1-2 region to the C-terminal part of a gp130 mutant, which was unable to associate with JAKs in the membrane-proximal region, did not restore JAK association [45] . This may point at the possibility that membrane proximity is crucial for receptor-JAK interaction to occur. However, it cannot be excluded that the structural integrity of the JAK interaction interface within the receptor depends on N-terminally adjacent sequences, i.e. the helix spanning the membrane which probably extends into the cytoplasmic region [45, 46] . It would be a great achievement to determine the three-dimensional structure of the membraneproximal region of a cytokine receptor, possibly in conjunction with a JAK or a fragment thereof.
The receptor not only serves as a docking site for JAKs. In addition, certain residues within gp130 have been identified to be crucial for JAK activation, e.g. substitution of Trp 652 with alanine (W652A) within the box1 region has no effect on JAK1 association but abrogates JAK1 activation. Signal transduction is even drastically impaired if only one chain within a gp130 dimer carries the W652A mutation [55] . Mutations with similar consequences (no JAK activation in spite of JAK association) have been described for the EpoR [59] , indicating that cytokine receptors in general contribute to the JAK-activation process.
The general structure of JAKs is shown in Figure 4 . The Cterminal tyrosine kinase domain is preceded by a pseudokinase domain, which itself is devoid of catalytic activity, but regulates the activity of the kinase domain [3] . JAKs also contain a predicted SH2 (Src homology 2) domain. It will be interesting to find out the significance of this domain for JAK function and to identify potential interaction partners.
The N-terminal region of JAKs comprises a FERM (fourpoint-one, ezrin, radixin and moesin) domain which is crucial for receptor association. FERM domains comprise three subdomains: subdomain F1 with a ubiquitin-like β-grasp fold, F2 with an acyl-CoA-binding-protein-like fold, and F3 which shares the fold of phosphotyrosine binding or PH (pleckstrin homology) domains. F1, F2 and F3 together form a compact clover-shaped structure [60] [61] [62] . A recent mutagenesis study has highlighted the importance of the F1 subdomain of JAK1 for the interaction with gp130 [63] .
Although the catalytic activity of JAKs is dispensible for receptor recruitment, it was described that alteration of the kinase domain structure of JAK3 by the kinase inhibitor staurosporine decreased the ability to bind to the common γ chain [64] . This indicates a potential interaction between the kinase domain and the FERM domain.
There are several reports describing other protein kinases (such as Src and Tec family kinases) that are associated with signal transduction of IL-6-type cytokines (for older references see [4] ). The Src family kinase Hck has recently been shown to associate with an acidic region (amino acids 771-811) of gp130 [65] . Deletion of these amino acids reduces IL-6-induced Hck kinase activity, ERK (extracellular-regulated kinase) activation, dephosphorylation of Pyk2 and proliferation of transfected pro-B Ba/F3 cells [65] . Cdk9 (cyclin-dependent kinase 9) was also found to bind to gp130, and the association increased upon IL-6 stimulation of HEK 293 cells over-expressing gp130 and Cdk9 [66] . PKCδ (protein kinase Cδ), a kinase implicated in serine phosphorylation of STAT3 (see below), has been found in a complex with gp130 upon IL-6 stimulation. PKCδ enhances the association of STAT3 with the receptor, which possibly involves the phosphorylation of Thr 890 of gp130 [67] . It will be interesting to define the respective contribution of these 'non-JAK' kinases to IL-6 signal transduction.
Another face of JAKs: determination of the receptor's fate
Apart from their role in signal transduction JAKs are important for the regulation of surface expression of at least some cytokine receptors.
Co-expression of JAK1, JAK2 and TYK2 substantially enhances the surface expression of the human OSMR. While kinase activity is dispensible for this effect, association of the JAKs to the box1/box2 region leads to the masking of a negative regulatory signal, potentially a previously uncharacterized endoplasmic reticulum retention/retrieval signal, that prevents efficient surface expression. This effect is also observed in cells with endogenous expression levels of the OSMR and JAKs: human fibrosarcoma cells lacking JAK1 express less OSMR at their surface compared with the parental cells, but transient transfection of JAK1 can again increase the amount of surface-expressed receptors [49] .
Similarly, JAK2 is crucial for EpoR surface expression. In this case it has been hypothesized that JAK2 supports the proper folding of the receptor [59] .
TYK2 is important for surface expression of the IFNα receptor 1 chain [68] . Recently, it has been found that TYK2 prevents receptor internalization [69] . Thus, the mechanisms how JAKs are involved in the regulation of surface expression seem to vary between receptor systems.
The STAT transcription factors: more nuts to crack?
Extensive studies have established the central role of STATs in IL-6-type cytokine signalling. The STAT family of transcription factors encompasses seven mammalian members, designated STAT1, -2, -3, -4, -5a, -5b and -6. The domain structure of STAT proteins comprises from N-to C-terminus an oligomerization domain, the so-called coiled-coil domain, the DNA-binding domain, the linker domain, the SH2 domain and the transactivation domain (Figure 4 ). An alternative denomination for the coiled-coil domain, the DNA-binding domain and the linker domain is 4-helix bundle, β-barrel and connector domain respectively. This knowledge is derived from the solved partial crystal structures of STAT4, as well as STAT1 and STAT3 [70] [71] [72] .
Activation of the STAT family members requires the transient association of the STATs with cytokine receptors [73, 74] . The classical view favours the recruitment of monomeric STAT proteins to the activated receptors, but there is evidence that preassociated STAT factors exist in higher molecular mass complexes prior to stimulation [75] [76] [77] [78] . Although the exact nature and role of the higher molecular mass complexes is not yet established and their presence does not exclude the recruitment of STAT factors in a monomeric state, their mere existence, however, suggests that STAT activation may be more complex than previously assumed. Recently, non-phosphorylated, as well as IL-6 activated phosphorylated, STAT3 and STAT1 pools were found to be present in plasma membrane rafts [11] . In addition, STAT3 was reported to be associated with both caveolin-1 and heat-shock protein-90 in these rafts, as well as in the cytosol [79] .
All IL-6-type cytokines potently activate STAT3, and to a minor extent STAT1 through their common receptor subunit gp130 [4] . In the cases of LIFR and OSMR, STAT3 and STAT1, as well as STAT5, activation has been observed, with OSMR being the most potent activator of STAT5 [56] . This activation may not require receptor tyrosine phosphorylation, but result from a direct interaction of STAT5 with JAKs [80] . For OSMRmediated STAT5 activation both mechanisms have been observed (C. Evers and H. M. Hermanns, unpublished work). The recruitment of STATs to the activated receptors has been shown to be mediated by their SH2 domain and requires the phosphorylation of receptor tyrosine motifs [74, [81] [82] [83] [84] . Although several gp130 motifs mediate STAT3 activation, they are not equivalent with respect to their potential to activate STAT factors and acute-phase protein gene promoters [87] . Subsequent to receptor binding, the STAT factors are phosphorylated on a single tyrosine residue (Tyr 701 in STAT1 and Tyr 705 in STAT3) [88, 89] . This leads to the formation of active STAT dimers, also shown to be mediated by their SH2 domains [90] . Interestingly, the STAT1 and STAT3 phosphotyrosine motifs (STAT1, pY 701 IKT; STAT3, pY 705 LKT) do not agree with the STAT3 consensus sequences deduced from the gp130 and LIFR recruitment sites [81, [84] [85] [86] . A conformational change in the SH2 domain may account for this dual specificity [91] .
An additional STAT3 tyrosine phosphorylation site (Tyr 657 ) was reported by Pfeffer et al. [92] as a binding site for PI3K (phosphoinositide 3-kinase). However, the location of Tyr 657 in the solved structure of STAT3β bound to DNA questions that Tyr 657 is able to recruit the SH2 domain of PI3K. Although Tyr 657 is partially exposed at the surface of the SH2 domain of STAT3, it builds up hydrophobic contacts with a number of hydrophobic amino acid side chains and is part of the hydrophobic core of the STAT3 SH2 domain. Phosphorylation of this Tyr 657 would severely impair the function of the SH2 domain, as it is located in the centre of the binding pocket responsible for specific recognition of phosphotyrosine motifs. In addition, the partially buried side chain of Tyr 657 would not be able to bind into the phosphotyrosine binding pocket of PI3K. This, together with the lack of reports by other groups confirming the phosphorylation of Tyr 657 , questions the relevance of this tyrosine phosphorylation site for STAT3 function.
Serine phosphorylation and methylation of STATs: making the nutshell even harder
In addition to tyrosine phosphorylation, other post-translational modifications were reported to affect STAT function.
Serine phosphorylation
Serine phosphorylation has been described for STAT1, -3, -5a and -5b. Although the site of serine phosphorylation in STAT1 and STAT3 has been identified as Ser 727 , there is presently no clear picture on the nature of the involved serine kinase(s).
In most studies small molecular mass inhibitors, as well as dominant negative kinases, have been used to identify the serine/ threonine kinases. Depending on the experimental system, i.e. the cell type and the cytokine/growth factor investigated, evidence for the involvement of PKCδ [93] [94] [95] [96] , p38 MAPK [93] , MEKK1 (MAPK/ERK kinase kinase 1) [97] , ERK [98] , JNK (c-Jun N-terminal kinase) and, most recently, the Ca 2+ /calmodulindependent kinase II [99] has been obtained.
Most investigators have found an increase in transcription of target genes upon cytokine-induced serine phosphorylation of STAT1, -3 and -5 [93, [98] [99] [100] [101] [102] . In prolactin-stimulated mammary epithelial cells serine phosphorylation has an impact on signal duration [101] .
In the case of STAT3 activation after IL-6 stimulation of HepG2 cells, two distinct pathways for the serine phosphorylation have been identified: one sensitive and the other insensitive to the serine/threonine kinase inhibitor H7 [98] . Earlier studies [103, 104] had already shown: (i) Ser 727 phosphorylation of STAT3 to occur slower than the phosphorylation of Tyr 705 ; (ii) dominantnegative Ras to have no effect on STAT3 Ser 727 phosphorylation; and (iii) the existence of an H7-sensitive serine/threonine kinase indicating that the MAPK pathway is not involved. These results were confirmed by Chung et al. [105] , who also observed that IL-6-induced STAT3 activation is MAPK independent, but sensitive to H7.
For several cell lines it has been reported that PKCδ associates IL-6 dependently with STAT3 and phosphorylates it on Ser 727 , leading to an inhibition of STAT3 DNA binding and transcriptional activity [94] . A sequential activation of Vav, Rac-1, MKK-4 (MAP kinase kinase 4) and PKCδ is necessary for the IL-6-mediated STAT3 Ser 727 phosphorylation and transactivation in HepG2 cells. Moreover, there is evidence that the PKCδ-mediated STAT3 Ser 727 phosphorylation occurs in the nucleus [95] . It is presently not clear how PKCδ is activated upon IL-6 stimulation.
Methylation of STATs
Another post-translational modification has only recently been recognized to play an important role in STAT function; Arg 31 of STAT1 was found to be specifically methylated by PRMT-1 (protein arginine methyltransferase-1). There was earlier evidence for a link between PRMT and the JAK/STAT pathway: PRMT-1 was found to associate with the IFNα/β receptor 1 [105a] ; and also a JAK-associated protein was identified as PRMT-5 [105b] .
STAT1 methylation is observed in the absence of cytokine stimulation, independent of tyrosine or serine phosphorylation, but requires the intact STAT1 SH2 domain. Compared with the unmethylated protein, methylated STAT1 has a higher tendency to associate with DNA, since its interaction with PIAS (protein inhibitor of activated STATs) 1 (see the subsection below entitled 'PIAS -more than inhibitors of activated STATs?') seems to be weaker [106] . Arg 31 is conserved among the STATs and it will be interesting to find out whether other STATs are also subject to methylation.
STAT nuclear translocation: not a one way ticket
In response to IL-6 stimulation, cytoplasmic STAT3 rapidly accumulates in the nucleus. Because of their size of 90 kDa that is far beyond the exclusion limit of the nuclear pore, STATs need to be actively translocated into the nucleus. Indeed, extracellularsignal-dependent translocation of STAT1 in response to IFN requires the nuclear import receptor NPI-1/importin-α5, which mediates translocation via a Ran-dependent mechanism [107] . Sensitivity to leptomycin suggests that nuclear export of STAT1 involves the nuclear export receptor CRM-1 that also acts in a Randependent manner [108, 109] . Nuclear accumulation is triggered by STAT dimerization in response to tyrosine phosphorylation. Tyrosine phosphorylation itself is not necessarily required for STAT nuclear translocation. Artificially dimerized STAT proteins that are not phosphorylated also accumulate in the nucleus [110, 111] .
A recent study [112] on STAT3 activation in response to EGF (epidermal growth factor) suggests that receptor-mediated endocytosis is required for shuttling of STAT3 from the plasma membrane to the perinuclear region. According to this study, STAT3 is associated with endocytotic vesicles during directed transport through the cytosol [112] . However, from an earlier study [113] , it was concluded that nuclear translocation of STAT1 in response to IFNγ does not require cytoskeletal structures, such as actin filaments or microtubules. There, a non-directional random-walk model was proposed for the cytoplasmic passage of STAT1. Furthermore, nuclear accumulation of constitutively active STAT proteins is independent from endocytosis, because in these cases the STATs are not recruited to any plasma membrane receptor [110, 114] . Also microinjected phosphorylated STAT1 protein readily concentrates in the nucleus without obvious involvement of endocytotic vesicles (U. Vinkemeier, personal communication). Thus there seems to exist no strict requirement for the targeted movement of endocytotic vesicles for STAT nuclear translocation to occur.
Most studies aimed at the identification of putative nuclear import signals [NLSs (nuclear localization signals)] or export signals [NESs (nuclear export signals)] were performed with STAT1. Nevertheless, mutagenesis studies on STAT5 provided the first evidence for a functional role of the DNA-binding domain in nuclear translocation [115] . In the DNA-binding domain of STAT1, initially an NES was postulated that comprises residues 399-410 [108] . Later it turned out that residues located within this short sequence stretch are important for the interaction of STAT1 with the import receptor importin-α5 and therefore for nuclear import of STAT1 [116, 117] . Adjacent to this sequence, basic residues (Lys 410 and Arg 413 ) were identified that also contribute to the NLS of dimeric STAT1 [117] [118] [119] . Two other NESs were characterized in the coiled-coil region of STAT1 (residues 302-314), both containing several leucine residues that are critical for their function [109, 120] . The functional overlap of DNA-binding, NLS and NES sequences points to a role for DNA binding in the regulation of nucleocytoplasmic shuttling of STAT proteins.
Previous studies suggested that tyrosine phosphorylation of STATs results in dimerization and nuclear translocation. Dephosphorylation of STAT within the nucleus leads to export from the nucleus [121] . Our recent investigations and work of others [117, 122, 123] led to the establishment of continous nucleocytoplasmic shuttling of STAT proteins that is independent from extracellular stimulation and phosphorylation. The finding of unphosphorylated STAT proteins within the nucleus [122] is consistent with the well-established role of unphosphorylated STATs as transcriptional coactivators [124, 125] . NLSs for this phosphorylation-independent shuttling are different from those for phosphorylation-induced nuclear accumulation, but are not yet identified [117] . Further evidence suggests that continuous nucleocytoplasmic shuttling of STAT proteins even occurs after stimulation and nuclear accumulation [126] .
Activation of MAPK cascades: one tyrosine to make things more complicated
Dimerization of IL-6-type cytokine receptors does not only lead to activation of the JAK/STAT-signalling pathway, but also to the induction of the MAPK cascade. Initial analyses concerning gp130-and LIFR-mediated activation of MAPKs identified the SHP2 (SH2-domain-containing tyrosine phosphatase)-binding site Tyr 759 of gp130 [81] and Tyr 974 of LIFR to be crucial for the activation of the MAPK cascade [127] . In contrast with gp130 and LIFR, the OSMR does not recruit SHP2. Nevertheless, the OSMR is also able to induce activation of the Ras-Raf-MAPK pathway. It has been demonstrated that the adaptor protein Shc (SH2-and collagen-homology-domain-containing protein) (Figure 4 ) is recruited to the receptor via Tyr 861 in the cytoplasmic region of the OSMR [128] (Figure 6 ).
According to the current view of the SHP2-dependent activation of MAPKs adopted from EGF and PDGF (platelet-derived growth factor) signal transduction, SHP2 links the Grb2-SOS (growthfactor-receptor-bound protein/Son of Sevenless) complex and/or Gab1 (Grb2-associated binder-1) to gp130 [127, 129, 130] . SHP2 is rapidly recruited to tyrosine-phosphorylated gp130 and becomes also phosphorylated in a JAK1-dependent manner [131] . Subsequently, tyrosine-phosphorylated SHP2 interacts with Grb2 [132] . Two C-terminal tyrosine residues within SHP2 (Tyr 542 and Tyr 580 ) are believed to interact with the Grb2-SOS complex. The alternative Shc-mediated pathway mediated by OSM also involves the adaptor protein Grb2 which is recruited to Tyr 317 -phosphorylated Shc. Finally, recruitment of SOS to the receptor complex at the membrane allows Ras activation, which in turn leads to the activation of the Ras-Raf-MAPK cascade. Thus the OSMR, unlike gp130 or the LIFR, uses the Shc-Grb2-SOS route for activation of MAPKs [128] .
Another degree of complexity is added by the fact that Gab1 is also involved in the activation of the Ras-Raf-MAPK cascade. Gab1 is a scaffolding adaptor protein which is targeted via a PH domain to the plasma membrane. Furthermore, it contains binding sites for Grb2, SHP2, PI3K, Crk, phospholipase Cγ and the c-Met receptor [129, 133, 134] . In response to IL-6, Gab1 is tyrosine phosphorylated and interacts subsequently with SHP2 and PI3K. Interestingly, no direct interaction of Gab1 and gp130 is required for its tyrosine phosphorylation. Nevertheless, mutation of Tyr 759 , the SHP2 recruitment site within gp130, impairs the interaction of Gab1 with SHP2 and PI3K, suggesting that binding of SHP2 to gp130 and its subsequent phosphorylation is a prerequisite for the interaction with Gab1. Finally, IL-6-induced association of Gab1 with SHP2 leads to activation of ERK2 [135] . As expected, Gab1-deficient fibroblasts show a markedly reduced MAPK activity in response to IL-6 [136] .
Although Gab1 integrates several signal transduction pathways, translocation of SHP2 to the membrane, in proximity to membrane anchored Ras, seems to be sufficient to mediate ERK activation, since expression of a fusion protein comprising the PH domain of Gab1 and active SHP2 induces constitutive MEK1 (MAPK/ERK kinase) and ERK2 activation [137] .
After EGF stimulation, SHP2 associated with Gab1 also regulates and counteracts PI3K binding to Gab1 [138] . Analogous mechanisms in respect to IL-6-type cytokine signalling should not automatically be expected, since even PDGF-and insulin-like growth factor 1-dependent PI3K activation is not affected by SHP2 [138] , suggesting that SHP2 acts in a strictly receptor specific manner.
Recently, a further mechanism for the regulation of the MAPK cascade by cytokines has been found by Cacalano et al. [139] . In response to IL-2, Epo, EGF, and PDGF, SOCS3 (suppressor of cytokine signalling 3) becomes tyrosine phosphorylated, and subsequently binds and inactivates Ras/GTPase-activating protein. This results in the inhibition of the GTPase activity of Ras, leading to a sustained Ras/GTP and MAPK activity [139] . Analogous observations for IL-6-type cytokines have not been reported.
The family of IL-6-type cytokines not only activates ERK1/2, a MAPK known for cellular processes that maintain cell survival, but also the stress-activated members of the MAPK family: p38 and JNK [140] [141] [142] (Figure 6 ). The signal transduction pathways resulting in their activation, however, remain poorly understood. A recent study by Schuringa et al. [95] postulated that the activation of JNK is involved in the serine phosphorylation of STAT3 after stimulation of hepatoma cells with IL-6. Using constitutive-active and dominant-negative variants of the signalling components, they delineated the signalling pathway leading to JNK activation and suggest the involvement of the GTP-exchange factor Vav, the small G-protein Rac and the MAPK kinase, MKK6. Their study is in contrast with the finding of Zauberman et al. [142] , which demonstrated an activation of p38 MAPK, but not JNK, in hepatoma cells and found an involvement of p38 MAPK in STAT3-mediated transcriptional activation of the acute-phase protein haptoglobin.
Activation of the PI3K cascade: the lipid connection
IL-6-type cytokines can lead to the activation of yet an additional signalling cascade involving PI3K. This enzyme modifies certain phosphatidylinositides, so that the serine/threonine kinase protein kinase B/Akt is recruited to the plasma membrane, where it becomes activated through phosphorylation by PDK1 (phosphoinositide-dependent kinase-1). Substrates of Akt include the forkhead transcription factor FKHR and the pro-apoptotic factor Bad (Bcl-2/Bcl-X L -antagonist, causing cell death), whose phosphorylation is associated with increased survival or cell growth. In cardiac myocytes gp130 conveys signals through this pathway which lead to prevention of doxorubicin-induced apoptosis [143] . Also, in basal cell carcinoma cells the PI3K pathway is crucially involved in the IL-6-mediated prevention of apoptosis which coincides with the up-regulation of the antiapoptotic protein Mcl-1 [144] . IL-6-induced activation of the PI3K/Akt pathway is involved in protection against apoptosis, as well as in enhanced proliferation of multiple myeloma cells [145] [146] [147] . Moreover, in human Hep3B hepatoma cells IL-6 leads to activation of the PI3K/Akt pathway necessary for the anti-apoptotic effect of IL-6 during transforming growth factor β treatment [148] . It should be noted, however, that PI3K activation upon IL-6 treatment is observed in a cell-type specific manner; e.g. no significant Akt activation could be observed in IL-6-treated HepG2 hepatoma cells [149] . The molecular mechanism linking gp130 engagement to the activation of the PI3K/Akt pathway is not well understood. After IL-6 stimulation the adaptor protein Gab1 (see the subsection above entitled 'Activation of MAPK cascades: one tyrosine to make things more complicated') interacts with PI3K [135] . Similarly, PI3K associates with the IRS-1 (insulin receptor substrate-1) adaptor in response to OSM [150] , suggesting that both IRS-1 and Gab1 may couple gp130 to PI3K activation.
MECHANISMS OF SIGNAL TERMINATION
To prevent overstimulation, Nature has invented sophisticated mechanisms to turn off cytokine-mediated signal transduction (see Figure 8 ).
Protein tyrosine phosphatases (PTPs): what goes up must come down
A key event in signal transduction of IL-6-type cytokines is the phosphorylation of components of the signal transduction cascade. Thus it is obvious that, besides kinases, phosphatases also have to be involved in proper signal transmission. First evidence for the contribution of a phosphatase in IL-6 signalling was obtained by the finding that the PTP SHP2 is recruited to the cytoplasmic Tyr 759 of activated gp130 [81, 151] . SHP2 is a ubiquitously expressed cytoplasmic PTP containing two N-terminal SH2 domains and a catalytic phosphatase domain in the C-terminal half of the protein (Figure 4) . The crystal structure of SHP2 suggests that, in the absence of a tyrosinephosphorylated binding partner, the N-terminal SH2 domain covers the active site and thereby inhibits the enzymic activity [152] . Binding of the SH2 domains to phosphotyrosine motifs of receptors or adapters unfolds the protein, leading to enzymic activity [153] [154] [155] . SHP2 also becomes activated by the phosphorylation of tyrosine residues 542 or 580 within the C-terminal part of the enzyme. Subsequently, these phosphotyrosines interact with the N-and C-terminal SH2-domains respectively, relieving the PTP domain from the N-terminal SH2-domain-mediated inhibition [156] (Figure 7) . Tyr 759 of gp130 appears to have multivalent functions for signalling; substitution with phenylalanine impairs SHP2 recruitment and phosphorylation [81] and leads to enhanced IL-6 [131, 157, 158] , as well as LIF and OSM, signal transduction [159] . In addition to SHP2, the feedback inhibitor SOCS3 also contributes to pTyr 759 -mediated inhibition (see the subsection below entitled 'The SOCS family of feedback inhibitors: natural born terminators', and Figure 8 ). On the other hand, the IL-6-induced activation of the MAPK cascade is impaired by mutation of Tyr 759 within gp130, indicating that SHP2, as an adaptor, has a positive function on the activation of the MAPK cascade (as shown in Figure 1 ). However, SHP2 also plays a negative regulatory role as a tyrosine phosphatase in the Jak/STAT pathway [160] (as indicated in Figure 8 ). Experiments in vivo underscore the in vitro findings in demonstrating that mice expressing gp130 lacking Tyr 759 display splenomegaly, lymphadenopathy and an enhanced acute-phase reaction [161] .
All tyrosine-phosphorylated signalling components are potential substrates for the SHP2 phosphatase. Overexpression of dominant-negative SHP2 mutants leads to enhanced receptor, JAK, STAT and SHP2 phosphorylation [160] . Since increased JAK activity also enhances activation of signalling molecules downstream of JAK, it is difficult to establish which proteins are direct substrates for SHP2 in vivo. Interaction of SHP2 with JAK1, JAK2 and TYK2, and phosphorylation of SHP2 by JAK1 and JAK2, have at least been shown to occur in vitro [131, 162] . Further evidence for STAT3 as a direct substrate of SHP2 comes from the detection of STAT3-SHP2 complexes [163] . In the case of STAT1, SHP2 has been described as a dual-specificity phosphatase that dephosphorylates pTyr 701 and pSer 727 [164] . Furthermore, the highly conserved N-terminal part of STAT1 and STAT3 appears to mediate sensitivity towards phosphatases, since STAT proteins lacking this domain are found to be hyperphosphorylated [165] [166] [167] .
Besides SHP2, further phosphatases are suggested to affect IL-6 signalling. The cytoplasmic variant of PTPε, PTPεC, is expressed in haematopoietic cells and has been shown to selectively inhibit IL-6-induced gp130, JAK and STAT activation [168] . Whereas SHP2 modulates the amount and amplitude of STAT3 activity [131, 158] , PTPεC affects the kinetics of the onset of STAT3 activation [169] .
Several other PTPs, such as PTP1B, CD45 and SHP1, have also been reported to be involved in JAK/STAT signalling [170] [171] [172] . The function of these phosphatases in the signal transduction of IL-6-type cytokines remains to be analysed in detail.
Early results suggested the presence of a nuclear phosphatase which counteracts IFNγ -activated STAT1 and contributes to its nuclear export [121, 173] . Meanwhile, this phosphatase has been identified as the nuclear isoform of the T-cell PTP TC45 [174, 175] . Interestingly, STAT1 methylated at Arg 31 is a better substrate for T-cell PTP than non-methylated STAT1. Since both T-cell PTP and PIAS1 associate with the N-terminus of STAT1 (see below), PIAS1 may prevent dephosphorylation by preferentially masking the T-cell PTP binding region of nonmethylated STAT1 [176] . Thus methylation not only supports STAT activity (by preventing PIAS association), but also promotes its inactivation by dephosphorylation.
PIAS -more than inhibitors of activated STATs?
The family of PIAS comprises five mammalian members: PIAS1, PIAS3, PIASxα, PIASxβ, and PIASy. Initially identified as Gu/RNA helicase II-binding protein (PIAS1) [177] , it rapidly became clear that PIAS proteins are important transcriptional co-regulators of the JAK/STAT pathway [178, 179] . PIAS1 inhibits STAT1 signalling [179] , but conversely enhances the transcriptional activity of nuclear hormone receptors [180] . Whereas PIAS1 specifically inhibits DNA binding of activated STAT1 and thus STAT1-mediated gene induction (after IFN stimulation) [179] , PIAS3 was found to be specific for the inhibition of STAT3-mediated gene expression (after IL-6 stimulation) [178] . The interaction of PIAS proteins with STAT factors seems to require tyrosine phosphorylation of the STAT proteins. As mentioned above, PIAS1 preferentially associates with unmethylated STAT1 [106] . However, the exact molecular mechanism of how PIAS negatively regulates STAT transcriptional activity needs to be elucidated. Recently, PIASy was found to also inhibit STAT1-mediated gene activation [181] . In contrast with PIAS1, however, it did not affect STAT1 DNAbinding activity. PIASy rather appears to act as a transcriptional co-repressor of STAT1.
While earlier studies suggested that PIAS proteins might act in the cytoplasm, the picture that emerges from recently published work is that at least some members of this family display their activity in the nucleus. Here, they are located in specific nuclear bodies [182, 183] attached to the nuclear scaffold [184] . With respect to this finding, it is of interest that PIAS proteins exhibit E3-SUMO (small ubiquitin-related modifier)-ligase activity [185, 186] . Sumoylation may play a critical role in targeting transcription factors to nuclear bodies, where they bind to other sumoylated proteins, such as PML (promyelocytic leukaemia) or the co-repressor Sp100, and thereby become transcriptionally active or inactive [186, 187] .
The SOCS family of feedback inhibitors: natural born terminators
With the discovery of the SOCS proteins several years ago, a new mechanism of inhibition emerged [188] [189] [190] [191] [192] . These inhibitors have also been designated CISs (cytokine-inducible SH2 proteins) or SSIs (STAT-induced STAT inhibitors). The eight members of this family (CIS and SOCS1-SOCS7) contain a central SH2 domain, as well as a C-terminal domain called a SOCS box (Figure 4) . Expression of SOCS proteins was found to be rapidly up-regulated by IL-6 (CIS, SOCS1, SOCS2 and SOCS3), LIF (CIS, SOCS1, SOCS2 and SOCS3), IL-11 (SOCS3) and OSM (CIS, SOCS1 and SOCS3) [32, 190, 192, 193] . As SOCS proteins are induced via the JAK/STAT pathway and subsequently inhibit STAT-mediated signal transduction, they are acting as classical feedback inhibitors. The detailed mechanism of inhibition, however, seems to differ between the various family members. CIS, which was the first member to be identified, was shown to compete with STAT5 for recruitment sites within the EpoR and to thereby modulate the JAK2/STAT5 pathway [189, 194] . SOCS1 and SOCS3 are functionally most related and potently inhibit IL-6-type cytokine signalling. Both have been shown to act on the JAKs, and thereby inhibit the phosphorylation of gp130, STATs and the JAKs themselves [190, 192] . As SOCS1 and SOCS3 act at the level of the JAKs they can affect the activation of different STAT factors depending on the receptor system. SOCS1 inhibits signal transduction by binding to the activation loop of the JAKs via its SH2 domain. The so-called extended SH2 subdomain and the KIR (kinase inhibitory region) of SOCS1, located N-terminally to the SH2 domain (Figure 4 ), also take part in the inhibition of JAKs. The KIR region is thought to bind to the substrate binding site of the kinase domain and thereby to inhibit its catalytic activity [195] . In contrast with SOCS1, despite the fact that it can also bind to JAKs and that it contains a KIR region [196] , SOCS3 associates with specific phosphotyrosine motifs within activated cytokine receptors, such as gp130, EpoR, leptin receptor and the granulocyte colony-stimulating factor receptor [197] [198] [199] [200] [201] [202] [203] .
For gp130, SOCS3 has been found to bind to the phosphotyrosine motif 759 [197, 198] , which is also the binding site for SHP2. In fact, the affinity of SOCS3 to bind to gp130 peptides is even slightly higher than that of SHP2 [204] . Thus the involvement of SHP2 and SOCS3 in pTyr 759 -mediated attenuation has been re-analysed to determine the individual contributions of both proteins. Although both SOCS3 and SHP2 are recruited to the same site within the native gp130, it is suggested that there are two largely distinct modes of negative regulation of gp130 activity: through the feedback inhibition by SOCS3 and/or the dephosphorylation of phosphorylated JAKs, receptors and STATs [160] .
The exact mechanism by which SOCS3 functions is not entirely clear, as it was also reported to bind to the activation loop of JAK2 via its SH2 domain [196, 199] . One possible explanation is that receptor recruitment of SOCS3 is a prerequisite for subsequent JAK binding. Binding studies with phosphopeptides suggest that SOCS3 binds pTyr 759 of gp130 with much higher affinity than pTyr 1007 within the activation loop of JAK2 [198] . However, the affinity for the double phosphorylated activation loop peptide (pTyr 1007 -pTyr 1008 ) of JAK2 is comparable with the affinities determined for SOCS3 recruiting receptor motifs like pTyr 401 of the EpoR (M. Hörtner, S. Haan and P. C. Heinrich, unpublished work). The phosphorylation status of the JAKs (single tyrosine phosphorylation of the activation loop versus double tyrosine phosphorylation) may thus influence the mode of inhibition by which SOCS3 acts. This difference in the inhibitory mechanisms of SOCS1 and SOCS3 is also reflected in the fact that SOCS1 blocks JAK activity more efficiently than SOCS3 [205] .
Another degree of complexity is added to the inhibitory mechanism of SOCS proteins by reports that they are also involved in the degradation of some of their binding partners. Recent work suggests that SOCS proteins may be part of E3-ubiquitin ligases in complex with elongins B and C, as well as Rbx1 (RING box protein 1) and Cul5 (cullin 5) [206, 207] . In this complex, the SOCS proteins interact with elongin C via the SOCS box. Consistent with the postulated E3-ligase function are new findings that SOCS1 targets JAK2, Tel-JAK2 and IRS1/2, as well as Vav, to degradation [208] [209] [210] [211] [212] . However, the implications of this interaction for the SOCS proteins themselves are not clear at present. Mutations within the box region of SOCS1, as well as serine phosphorylation, which disrupt elongin C binding, have been shown to stabilize SOCS1 [213, 214] . Other reports, however, suggest that elongin C binding can stabilize SOCS1 and that the disruption of the interaction leads to proteasomal degradation of SOCS1 [206, 215] . In the case of SOCS3, tyrosine phosphorylation in response to IL-2, Epo, EGF and PDGF was reported [139, 216] . Phosphorylation occurs at two tyrosine residues (Tyr 204 and Tyr 221 ) within the SOCS box and phosphorylation of Tyr 221 recruits p120 RasGAP leading to sustained ERK activation [139] . As elongin C binds to the SOCS box, it is conceivable that tyrosine phosphorylation of SOCS3 also affects elongin C binding and SOCS3 stability.
MODULATION OF SIGNAL TRANSDUCTION
The topics covered in the previous section on signal termination represent rather linear types of regulation. However, a more complex network of regulatory mechanisms for the modulation of cytokine signalling exists.
Regulation of cytokine availability: life and death of the party
An important way to modulate the availability of cytokines is by regulating the half-life of their corresponding mRNAs, which are generally short-lived due to AU-rich sequences in their 3 -untranslated regions. The stress-activated p38 MAPK has been shown to play an important role in stabilizing the mRNA of many cytokines, including IL-6, by activation of MK2 (MAPKAPK2, MAPK-activated protein kinase 2) [217] . More recently this finding was further corroborated. It was shown in MK2-deficient macrophages that the half-life of IL-6 mRNA was reduced by more than 10-fold. Deletion of the AU-rich element of the TNFα (tumour necrosis factor-α) mRNA abrogates the effect of MK-2 [218] . Other signalling pathways have been shown to induce stabilization of cytokine mRNAs as well: the JNK pathway induces stabilization of the short-lived IL-2 mRNA [219] , and PI3K activation induces stabilization of IL-3 mRNA [220] . The exact mechanism by which signalling influences the stability of cytokine mRNAs still needs to be elucidated, but several reports implicate a function of AU-rich-element-binding regulators, such as tristetraproline and its homologue butyrate-response factor-1, Hu antigen R, heterogeneous nuclear ribonucleoprotein-D0/AUF1 and others. IL-6 protein availability might also be regulated by cytokine proteolysis. At sites of inflammation IL-6 induces the release of the serine proteases elastase, proteinase 3 and cathepsin G from neutrophils, which in turn degrade IL-6 [221] .
Half-lives of signalling components: party as long as you live
Of course, signal transduction by different players involved in a pathway depends on the availability of these proteins. A critical balance of protein synthesis and degradation also affects IL-6-type cytokine signal transduction. It has been reported that the half-lives of the various players involved in IL-6 signalling differ substantially (Table 1) [222, 223] . Whereas the feedback inhibitors SOCS1, SOCS2 and SOCS3 are very short-lived, STAT1, STAT3α and SHP2 have slow turnover rates. Interestingly, the half-life of STAT3β, a splice variant of STAT3α, is reduced by almost 50 % compared with the half-life of STAT3α. The Janus kinases JAK1, JAK2, TYK2 and gp130 show intermediate half-lives. These differences suggest that signalling components requiring posttranslational modifications for their activation are long-lived, whereas the activity of short-lived proteins is regulated mainly at the transcriptional level. It makes sense that very potent inhibitors like the SOCS proteins undergo a rapid turnover. New data suggest that post-translational modifications of these inhibitors may be a means to further regulate their activity by prolonging or shortening their half-lives (see earlier section entitled The SOCS family of feedback inhibitors: natural born terminators).
The difference in half-lives between STAT3α and STAT3β is possibly one feature contributing to the functional differences between the two transcription factors. For STAT3β both positive and negative regulatory functions have been reported [224] [225] [226] [227] [228] . Further studies are required to clarify these conflicting results.
Cross-talk of inflammatory cytokines: how MAPKs and NF-κB (nuclear factor κB) talk to STATs
The inflammatory cascade underlying the acute-phase response is largely controlled by the action of different mediators released under inflammatory conditions. Upon activation, blood monocytes and tissue macrophages release a set of primary inflammatory mediators such as IL-1β and TNFα. There is strong evidence indicating that IL-6-induced signalling and transcriptional activation are modulated at levels of signal transduction upstream from gene transcription. For example, LPS (lipopolysaccharide) and the pro-inflammatory cytokine TNFα have been shown to inhibit IL-6-mediated STAT3 activation in macrophages. This inhibition is most likely due to induction of the de novo synthesis of the JAK-inhibitor SOCS3 [229] . A similar mechanism has been discovered for IFNγ signalling, where LPS inhibits IFNγ -dependent STAT1 activation also via the induction of SOCS3 [230] . Additional mechanisms for inhibiting IL-6 signalling by pro-inflammatory cytokines may exist, since other data show that IL-1, TNF-α and LPS inhibit IL-6-dependent STAT activation in macrophages through mechanisms which do not depend on de novo protein synthesis [231, 232] . Interestingly, both SOCS3-dependent and SOCS3-independent inhibitory mechanisms of pro-inflammatory stimuli depend on the p38 stress kinase [229, 231, 233] . Similarly other MAPKs down-regulate IL-6-induced STAT3 activation. For example, the inhibitory effect of ionomycin or the phorbol ester PMA on IL-6-mediated STAT activation occurs rapidly and does not require de novo protein synthesis. Instead ERK1/2 MAPK were found to play a crucial role [234] .
IL-1β is also known to inhibit IL-6-induced acute-phase protein synthesis in hepatocytes [235] . However, no SOCS3 induction is observed upon IL-1β stimulation of human hepatoma cells. Instead, NF-κB was identified as a mediator for IL-1β-dependent suppression of IL-6-induced α 2 M (α 2 -macroglobulin) expression in liver cells [236] .
STAT-binding sites are often in close proximity to binding sites for other transcription factors, such as nuclear factor-IL6 [237] , NF-κB [238] , activator protein-1 [224, [239] [240] [241] and glucocorticoid receptor [242] , making a co-operative action of these factors with STATs in gene regulation most likely. Moreover, in the promoters of the rat α 2 M and the human α 1 -antichymotrypsin genes, STAT3-binding sites are arranged as a tandem [243, 244] , suggesting that formation of multimers on clustered binding sites also represents a regulatory step in STATdependent gene activation. This tandem organization of STAT-binding sites has also been emphasized to be essential for binding of tetrameric STAT3 to the α 2 M promoter [245] .
The first evidence for a competition of STAT3 and NF-κB for the α 2 M promoter binding was provided by Zhang and Fuller [246] on an isolated binding site within the α 2 M promoter. Interestingly, although NF-κB acts as a competitive inhibitor for STAT3 DNA-binding, at least one intact NF-κB and one intact STAT3 consensus site is crucial for the STAT3-dependent activation of the α 2 M gene promoter [236] , suggesting that a balanced ratio of NF-κB and STAT3 is essential for activating the α 2 M promoter. This indicates a dual, negative as well as positive, regulatory function of NF-κB in acute-phase protein gene induction.
A similar contribution of NF-κB to the regulation of other acute-phase proteins, such as α 1 -antichymotrypsin [236] and fibrinogen [247] , may indicate the general relevance of this new mechanism for controlling acute-phase protein gene expression. A recent report [248] describing a CBP [CREB (cAMP response element binding factor)-binding protein]-mediated synergistic transcriptional activation of STAT1 and NF-κB of the CXC9 gene further supports this idea.
STAT action within the transcriptosome: where transcription factors gather
Most eukaryotic transcription factors interact with histone acetyltransferases and transcriptional co-activators such as CBP/p300, although the composition of the individual co-activator complexes may vary [249] . The C-terminal transactivation domains of STAT1, STAT3 and STAT5 are known to interact with CBP/p300 [239, [250] [251] [252] . This interaction is further modulated by Nmi (N-Myc interactor) which augments CBP recruitment to STAT1 and STAT5, and potentiates IL-2 and IFNγ signalling [253] . Interestingly, Nmi itself is induced by IL-2 and IFNγ , indicating a positive feedback loop within this signal transduction. Whether Nmi also influences IL-6-type cytokine signalling remains speculation.
CBP/STAT interactions also contribute to negative regulation of gene expression by competition of transcription factors for a limited amount of CBP. Such a regulatory function has been shown for STAT1 which abolishes activator protein-1/ets transcriptional activity by competing for CBP binding [239] . By a similar mechanism STAT5B limits NF-κB-mediated signalling [254] .
Not only the lack of histone actetyltransferase activity may counteract STAT-mediated gene induction. Also, a contribution of histone deacetylases to the inhibition of STAT5-dependent promoter activation has been suggested. The nuclear receptor co-repressor SMRT (silencing mediator of retinoic and thyroid hormone receptors) is a potential binding partner for STAT5 and represses STAT5-dependent transcription [255] . Since both Nmi and SMRT interact with the coiled-coil domain of STAT5, the balance between bound co-activators and co-repressors may determine the activity of the transcription factor.
STAT3 transcriptional activity can also be enhanced by interaction with other transcription factors. Interesting examples are the forkhead transcription factor FKHR and EZI (endothelial cell-derived zinc-finger protein). FKHR specifically enhanced the activity of STAT3-dependent promoters, such as the α 2 M promoter, but not that of a STAT5-responsive promoter. Furthermore, FKHR and STAT3 can be co-immunoprecipitated and co-localize in the nucleus of IL-6-treated HepG2 cells [149] . These results indicate that FKHR can modulate the IL-6-induced transcriptional activity by enhancing STAT3 action. FKHR is inactivated by Akt/protein kinase B-mediated serine/threonine phosphorylation. This may explain previous findings describing an attenuation of the IL-6-mediated stimulation of acute-phaseprotein synthesis by insulin and other growth factors which activate the PI3K/Akt pathway [256, 257] .
The nuclear zinc-finger protein EZI was first recognized as an OSM-inducible gene product, but is expressed rather ubiquitously [258] . STAT3 and EZI physically interact as demonstrated by co-immunoprecipitation. Interestingly, an EZI mutant predominantly localized in the cytoplasm inhibited nuclear localization of STAT3, as well as STAT3-mediated transactivation. Thus, EZI may augment STAT3 activity by keeping it in the nucleus.
PERSPECTIVES
With more and more structural data on signalling components becoming available and allowing a better evaluation (or reevaluation) of previously performed mutagenesis studies, it is tempting to believe that signalling pathways will soon be completely understood. However, for some key components such data are still missing. For example, no data on the structure and conformational states of the cytoplasmic parts of cytokine receptors are available. Are they without structure at all or is there some kind of tight or loose structure that is induced or modified by the recruitment of signalling components (see Figure 5 )? In addition, insight into the three-dimensional structures of JAKs and SOCS proteins would be extremely valuable.
Even if all interactions between the components of the Jak/ STAT cascade were known, the signalling pathway would be still far from being fully understood. Additional complexity arises from newly discovered functions for the players involved and from the existence of a multitude of cross-talk mechanisms. Yet again, the cross-talk between the signalling pathways depends on the cell type. Furthermore, the biological outcome of a cytokine signal varies between different cells and their states of differentiation.
There are rare attempts to represent this emerging complexity in mathematical models. In most cases the quality of the models suffers from the lack of sufficient quantitative experimental data. Thus many ambitious efforts still have to be made to fill these gaps.
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